Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Phase 3
Active, not recruiting
NCT03173248
| Condition | Newly Diagnosed Acute Myeloid Leukemia, Untreated AML, AML Arising From Myelodysplastic Syndrome, Leukemia, Myeloid, Acute |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Institut de Recherches Internationales Servier |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 146 participants |
|---|
| Interventions | AG-120, Azacitidine |
|---|
| Start date | Jun 26, 2017 |
|---|
| Completion date | Mar 18, 2021 |
|---|
| Results posted | Mar 23, 2023 |
|---|
Summary
Study AG120-C-009 is a global, Phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of AG-120 (ivosidenib) + azacitidine vs placebo + azacitidine in adult participants with previously untreated IDH1m AML who are considered appropriate candidates for non-intensive therapy. The primary endpoint is event-free survival (EFS). The key secondary efficacy endpoints are overall survival (OS), rate of complete remission (CR), rate of CR and complete remission with partial hematologic recovery (CRh), and overall response rate (ORR). Participants eligible for study treatment based on Screening assessments will be randomized 1:1 to receive oral AG-120 or matched placebo, both administered in combination with subcutaneous (SC) or intravenous (IV) azacitidine. An estimated 200 participants will take part in the study.
Event-Free Survival (EFS)
Up to Week 24 · months
| AG-120 + Azacitidine | 0.03 months |
|---|
| Placebo + Azacitidine | 0.03 months |
|---|
| p-value | 0.0011 |
|---|
| Hazard Ratio (HR) | 0.33 (95% CI 0.16–0.69) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.